Literature DB >> 3499878

Alleviation of cyclosporine nephrotoxicity with verapamil and ATP-MgCl2. Mitochondrial respiratory and calcium studies.

B E Sumpio1, A E Baue, I H Chaudry.   

Abstract

Although recent studies have shown that combined treatment with verapamil and ATP-MgCl2 (ATP) prevents cyclosporine (CyA)-induced nephrotoxicity, the mechanism of these effects remains unknown. To study this, rat kidneys were perfused at 100 mmHg for 100 minutes with Krebs buffer containing 7.5 g/dL of albumin and substrates. After an equilibration period of 30 minutes, 500 ng/mL CyA was added. In some experiments 1 microgram/mL verapamil was added 10 minutes prior to CyA and in others 2 mM ATP was added to CyA. At the end of the perfusion, cortical mitochondria (mito) were isolated and mito Ca2+ and Mg2+ (mumoles/g protein) and respiratory control ratios (RCR) were measured. In addition, total tissue Ca2+ and Mg2+ levels were measured. The results indicate that CyA treatment leads to an accumulation of mito Ca2+ and a decrease in ADP/O ratio. Simultaneous administration of ATP with CyA led to an increased mito Ca2+ accumulation and depressed RCR, which were corrected by verapamil pretreatment. The combination of verapamil pretreatment and ATP cotreatment with CyA increased tissue ATP levels from 0.8 +/- 0.4 (control) to 1.4 +/- 0.1 mumol/g. This pharmacologic regimen may prevent CyA-induced nephrotoxicity by preventing mito Ca2+ accumulation and by preserving mitochondrial respiratory function. This allows a more efficient generation of ATP and consequently preservation of renal function.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3499878      PMCID: PMC1493310          DOI: 10.1097/00000658-198711000-00017

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  21 in total

1.  A study of Ca 2+ metabolism in kidney mitochondria during acute uranium intoxication.

Authors:  E Carafoli; R Tiozzo; I Pasquali-Ronchetti; R Laschi
Journal:  Lab Invest       Date:  1971-12       Impact factor: 5.662

2.  Giant mitochondria, renal transplant biopsy, and cyclosporin A.

Authors: 
Journal:  Lancet       Date:  1981-07-18       Impact factor: 79.321

3.  Experimental cyclosporin A nephrotoxicity.

Authors:  P H Whiting; A W Thomson; J T Blair; J G Simpson
Journal:  Br J Exp Pathol       Date:  1982-02

4.  Mitochondrial calcium accumulation and respiration in ischemic acute renal failure in the rat.

Authors:  D R Wilson; P E Arnold; T J Burke; R W Schrier
Journal:  Kidney Int       Date:  1984-03       Impact factor: 10.612

5.  Improved mitochondrial function following ischemia and reflow by ATP-MgCl2.

Authors:  I H Chaudry; M Ohkawa; M G Clemens
Journal:  Am J Physiol       Date:  1984-05

6.  Alterations in renal cortex cation homeostasis during mercuric chloride and gentamicin nephrotoxicity.

Authors:  J M Weinberg; P G Harding; H D Humes
Journal:  Exp Mol Pathol       Date:  1983-08       Impact factor: 3.362

7.  Verapamil inhibition of lymphocyte proliferation and function in vitro.

Authors:  M A McMillen; T Lewis; B M Jaffe; R B Wait
Journal:  J Surg Res       Date:  1985-07       Impact factor: 2.192

8.  Correlated effluxes of adenine nucleotides, Mg2+ and Ca2+ induced in rat-liver mitochondria by external Ca2+ and phosphate.

Authors:  F Zoccarato; M Rugolo; D Siliprandi; N Siliprandi
Journal:  Eur J Biochem       Date:  1981-02

9.  Kinetics, competition, and selectivity of tubular absorption of proteins.

Authors:  B E Sumpio; T Maack
Journal:  Am J Physiol       Date:  1982-10

10.  Mitochondrial bioenergetics during the initiation of mercuric chloride-induced renal injury. II. Functional alterations of renal cortical mitochondria isolated after mercuric chloride treatment.

Authors:  J M Weinberg; P G Harding; H D Humes
Journal:  J Biol Chem       Date:  1982-01-10       Impact factor: 5.157

View more
  1 in total

Review 1.  Cyclosporin A and cardioprotection: from investigative tool to therapeutic agent.

Authors:  Derek J Hausenloy; E A Boston-Griffiths; D M Yellon
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.